Darya Pon`kina

Mrs. Darya Pon`kina


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DPDarya Pon`kina
Darya Pon`kina
SKSergey Kuranov
Sergey Kuranov
MMMariya Marenina
Mariya Marenina
YMYulia Meshkova
Yulia Meshkova
NZNataliya A. Zhukova
Nataliya A. Zhukova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide. Several classes of hypoglycemic drugs are used to treat it, but various side effects limit their clinical use. Consequently, the search for new anti-diabetic agents remains an urgent task for modern pharmacology. In this investigation, we examined the hypoglycemic effects of bornyl-containing benzyloxyphenylpropanoic acid derivatives (QS-528 and QS-619) in a diet-induced model of T2DM. Animals were given the tested compounds per os at a dose of 30 mg/kg for 4 weeks. At the end of the experiment, compound QS-619 demonstrated a hypoglycemic effect, while QS-528 showed hepatoprotection. In addition, we performed a number of in vitro and in vivo experiments to study the presumed mechanism of action of the tested agents. Compound QS-619 was determined to activate the free fatty acid receptor-1 (FFAR1) similarly to the reference agonist GW9508 and its structural analogue QS-528. Both agents also increased insulin and glucose-dependent insulinotropic polypeptide concentrations in CD-1 mice. Our results indicate that QS-619 and QS-528 are probably full FFAR1 agonists.

3 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
DPDarya Pon`kina
Darya Pon`kina
SKSergey Kuranov
Sergey Kuranov
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
NZNataliya Zhukova
Nataliya Zhukova
YMYulia Meshkova
Yulia Meshkova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Free fatty acid receptor-1 (FFAR1) is one of the possible therapeutic targets in the search for new hepatoprotective drugs. FFAR1 agonists were found to have hypolipidemic, antifibrotic, anti-inflammatory, antiproliferative and antioxidant effects in addition to hypoglycemic action. In this work, we conducted a study of the hepatoprotective effect of the compound QS-528 (previously discovered as an agonist of FFAR1) at doses of 60, 90, 120 and 150 mg/kg on carbon tetrachloride (CCl4)-induced liver injury. At the end of the experiment, a biochemical blood assay demonstrated that the introduction of QS-528 dose-dependently reduces the levels of liver enzymes (AST, ALT and ALKP). Histological and morphometric studies of animals’ livers treated with QS-528 at doses of 120 and 150 mg/kg showed a decrease in degenerative/necrotic changes in hepatocytes and an increase in the regenerative activity of the liver. In addition, no toxicity at a single oral dose of 1000 mg/kg and an increase in HepG2 cell viability in vitro were found. Thus, the compound QS-528 was found to exhibit a hepatoprotective effect against CCl4-induced toxic liver damage.

Verified
Journal Article
Open access
PDF file
SKSergey Kuranov
Sergey Kuranov
DPDarya Pon`kina
Darya Pon`kina
YMYulia Meshkova
Yulia Meshkova
MMMariya Marenina
Mariya Marenina
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Free fatty acid receptor-1 (FFAR1) agonists are promising candidates for therapy of type 2 diabetes because of their ability to normalize blood sugar levels during hyperglycemia without the risk of hypoglycemia. Previously, we synthesized compound QS-528, a FFA1 receptor agonist with a hypoglycemic effect in C57BL/6NCrl mice. In the present work, structural analogs of QS-528 based on (hydroxyphenyl)propanoic acid bearing a bornyl fragment in its structure were synthesized. The seven novel compounds synthesized were structural isomers of compound QS-528, varying the positions of the substituents in the aromatic fragments as well as the configuration of the asymmetric center in the bornyl moiety. The studied compounds were shown to have the ability to activate FFAR1 at a concentration of 10 μM. The cytotoxicity of the compounds as well as their effect on glucose uptake in HepG2 cells were studied. The synthesized compounds were found to increase glucose uptake by cells and have no cytotoxic effect. Two compounds, based on the meta-substituted phenylpropanoic acid, 3-(3-(4-(((1R,2R,4R)-1,7,7-trimethylbicyclo-[2.2.1]heptan-2-ylamino)methyl)benzyloxy)phenyl)propanoic acid and 3-(3-(3-(((1R,2R,4R)-1,7,7-trimethylbicyclo [2.2.1]heptan-2-ylamino)methyl)benzyloxy)phenyl)propanoic acid, were shown to have a pronounced hypoglycemic effect in the oral glucose tolerance test with CD-1 mice.

1 November 2022 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
DPDarya Pon`kina
Darya Pon`kina
SKSergey Kuranov
Sergey Kuranov
Irina Vasilievna SorokinaIrina Vasilievna Sorokina
Irina Vasilievna Sorokina
YMYulia Meshkova
Yulia Meshkova
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by impaired lipid and carbohydrate metabolism, and is characterized by fatty degeneration, necrosis, inflammation, and fibrosis of hepatocytes. There are currently no approved drugs for the treatment of NAFLD, so their search remains an urgent task for present pharmacology. Previously, N-alkylated isobornylamine (compound 1), a GPR40 agonist, at a dose of 30 mg/kg was shown to resolve fatty liver degeneration in C57Bl/6Ay mice and improve glucose tolerance. As a result, we continued to study the hepatoprotective effect of compound 1 on CCl4-induced chronic hepatotoxicity model in CD-1 mice. Compound 1 was administered per os at doses of 60, 90, 120 and 150 mg/kg daily for 3 weeks, as well as the reference drug silymarin at a dose of 100 mg/kg. At the end of the experiment, a biochemical blood assay was carried out, which showed that compound 1 dose-dependently reduces ALT, AST and ALKP. According to the results of a histological and morphometry liver examination, compound 1 was found to reduce the severity of degenerative-necrotic changes in hepatocytes. More pronounced improvements in doses of 120 and 150 mg/kg were noted. Thus, isobornylamine derivative exhibits a hepatoprotective effect not only in metabolic liver injury, but also in CCl4-induced chronic liver damage.